Table 2 Objective response rates
n, % | Veliparib + FOLFIRI ± Bevacizumab (N = 65) | Placebo + FOLFIRI ± Bevacizumab (N = 65) |
|---|---|---|
ORR [95% CI] | 37 (57%) [44.0, 69.2] | 40 (62%) [48.6, 73.3] |
Best response | ||
Complete response | 2 (3%) | 2 (3%) |
Partial response | 35 (54%) | 38 (59%) |
Stable disease | 20 (31%) | 19 (29%) |
Disease progression | 3 (5%) | 4 (6%) |
Incomplete data | 5 (8%) | 2 (3%) |
